Dr. Reddy's Laboratories Ltd (RDY)
NYSE: RDYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
RDY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.22B
- P/E (TTM)
- 28.53
- Forward P/E
- 19.05
- EPS (TTM)
- $0.43
- Dividend yield
- 65.20% ($8.00)
- Ex-dividend date
- Jul 24, 2026
- 52-week range
- 11.36 – 15.67
- Day range
- 12.22 – 12.37
- Volume / Avg
- 3.12M / 2.89M
- Beta
- —
- Shares outstanding
- 832.99M
- Next earnings
- Oct 23, 2026
52-week range
RDY stock today
On Oct 7, RDY ended the session at $12.27, shedding $0.22 (1.76%), versus the S&P 500's 0.22% decline. Shares are 21.7% below their 52-week high of $15.67, set on Jun 26, 2026 and 8.0% above the 52-week low of $11.36, in the middle of the past year's range. RDY is down 12.6% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 12.5%.
At 28.5x trailing earnings, Dr. Reddy's Laboratories trades below the peer-group median of 134.2x. Its forward P/E of 19.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 23; analysts expect EPS of $0.16. Dr. Reddy's Laboratories pays an annual dividend of $8.00 per share, a 65.20% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Dr. Reddy's Laboratories
Company profileDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Erez Israeli M.B.A.
- Headquarters
- Hyderabad
- Employees
- 27,527
- Website
- drreddys.com
Financial highlights
Full financialsIn fiscal 2025, Dr. Reddy's Laboratories generated $3.81 billion in revenue, up 13.8% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $663.0 million (-0.7% year over year), for a net margin of 17.4% versus a median of 11.2% in the prior 5 years. Gross margin was 58.5% (down from 58.6%) and operating margin 22.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.81B | $3.35B | $2.99B | $2.83B | $2.59B |
| Growth | +13.76% | +11.97% | +5.87% | +8.94% | +12.00% |
| Net income | $663.00M | $668.00M | $548.00M | $311.00M | $236.00M |
| EPS (diluted) | $0.79 | $4.01 | $3.30 | $1.87 | $1.52 |
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$13.22+7.74%
- Strong buy 0
- Buy 2
- Hold 2
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 23, 2026
- EPS estimate
- $0.16
Dividends
Dividend history- Annual dividend
- $8.00
- Dividend yield
- 65.20%
- Last payment
- $0.083
- Ex-dividend date
- Jul 24, 2026
Dr. Reddy's Laboratories peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BMRNBioMarin Pharmaceutical Inc. | 55.20 | -1.81% | $10.69B | vs RDY |
| ELANElanco Animal Health Incorporated | 22.36 | -0.53% | $11.17B | vs RDY |
| MDGLMadrigal Pharmaceuticals Inc. | 487.72 | -1.76% | $11.27B | vs RDY |
| PTGXProtagonist Therapeutics Inc. | 140.92 | +1.61% | $9.12B | vs RDY |
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs RDY |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs RDY |
| CYTKCytokinetics Incorporated | 61.12 | -0.37% | $8.50B | vs RDY |
| TGTXTG Therapeutics Inc. | 52.95 | +1.46% | $8.11B | vs RDY |
Indexes, lists and sector
Appears in lists
Dr. Reddy's Laboratories stock FAQ
What is Dr. Reddy's Laboratories's stock price today?
RDY last traded at $12.27 as of Oct 7, 4:00 PM EDT, down 1.76% on the day. Prices are delayed at least 15 minutes.
Does Dr. Reddy's Laboratories pay a dividend?
Yes. Dr. Reddy's Laboratories pays $8.00 per share annually, a 65.20% yield. The most recent dividend of $0.083 had an ex-dividend date of Jul 24, 2026.
When is Dr. Reddy's Laboratories's next earnings date?
Dr. Reddy's Laboratories is expected to report earnings on Friday, October 23, 2026. Analysts expect EPS of $0.16.
What is RDY's P/E ratio?
RDY trades at a trailing P/E ratio of 28.53 and a forward P/E of 19.05, compared with a median of 134.2 for its closest peers.
Who is Dr. Reddy's Laboratories's CEO?
Mr. Erez Israeli M.B.A. is the chief executive officer of Dr. Reddy's Laboratories Ltd, which has about 27,527 employees.
Has RDY ever split its stock?
Yes. The most recent RDY stock split was a 5-for-1 split on Nov 5, 2024, one of 2 splits on record.
What is the RDY 52-week high?
The 52-week high for RDY is $15.67 and the 52-week low is $11.36. The stock is currently 21.7% below its high.